These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16305992)

  • 1. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.
    Costanzi J; Sidransky D; Navon A; Goldsweig H
    Cancer Invest; 2005; 23(7):643-50. PubMed ID: 16305992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.
    Beck AK; Pass HI; Carbone M; Yang H
    Future Oncol; 2008 Jun; 4(3):341-9. PubMed ID: 18518759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleases as novel chemotherapeutics : the ranpirnase example.
    Lee JE; Raines RT
    BioDrugs; 2008; 22(1):53-8. PubMed ID: 18215091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell.
    Drugs R D; 2007; 8(2):120-4. PubMed ID: 17324010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Onconase: a ribonuclease with antitumor activity].
    Zwolińska M; Smolewski P
    Postepy Hig Med Dosw (Online); 2010 Feb; 64():58-66. PubMed ID: 20173221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.
    Lee I
    Expert Opin Biol Ther; 2008 Jun; 8(6):813-27. PubMed ID: 18476793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.
    Pavlakis N; Vogelzang NJ
    Expert Opin Biol Ther; 2006 Apr; 6(4):391-9. PubMed ID: 16548765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
    Vogelzang NJ; Aklilu M; Stadler WM; Dumas MC; Mikulski SM
    Invest New Drugs; 2001; 19(3):255-60. PubMed ID: 11561684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.
    Porta C; Paglino C; Mutti L
    Biologics; 2008 Dec; 2(4):601-9. PubMed ID: 19707441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
    Mikulski SM; Costanzi JJ; Vogelzang NJ; McCachren S; Taub RN; Chun H; Mittelman A; Panella T; Puccio C; Fine R; Shogen K
    J Clin Oncol; 2002 Jan; 20(1):274-81. PubMed ID: 11773179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB.
    Tsai SY; Ardelt B; Hsieh TC; Darzynkiewicz Z; Shogen K; Wu JM
    Int J Oncol; 2004 Dec; 25(6):1745-52. PubMed ID: 15547713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo.
    Kiesgen S; Arndt MAE; Körber C; Arnold U; Weber T; Halama N; Keller A; Bötticher B; Schlegelmilch A; Liebers N; Cremer M; Herold-Mende C; Dyckhoff G; Federspil PA; Jensen AD; Jäger D; Kontermann RE; Mier W; Krauss J
    Cancer Lett; 2015 Feb; 357(1):364-373. PubMed ID: 25434798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
    Ardelt W; Shogen K; Darzynkiewicz Z
    Curr Pharm Biotechnol; 2008 Jun; 9(3):215-25. PubMed ID: 18673287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binase and other microbial RNases as potential anticancer agents.
    Makarov AA; Kolchinsky A; Ilinskaya ON
    Bioessays; 2008 Aug; 30(8):781-90. PubMed ID: 18623073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of enhanced tumoricidal efficacy of multiple small dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer.
    Lee I; Shogen K
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):337-46. PubMed ID: 18064463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic ribonucleases and chimeras in cancer therapy.
    Youle RJ; Newton D; Wu YN; Gadina M; Rybak SM
    Crit Rev Ther Drug Carrier Syst; 1993; 10(1):1-28. PubMed ID: 8472310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Why ribonucleases cause death of cancer cells].
    Il'inskaia ON; Makarov AA
    Mol Biol (Mosk); 2005; 39(1):3-13. PubMed ID: 15773542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribonucleases as potential modalities in anticancer therapy.
    Ardelt W; Ardelt B; Darzynkiewicz Z
    Eur J Pharmacol; 2009 Dec; 625(1-3):181-9. PubMed ID: 19825371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic activity of the amphibian ribonucleases onconase and r-amphinase on tumor cells from B cell lymphoproliferative disorders.
    Smolewski P; Witkowska M; Zwolinska M; Cebula-Obrzut B; Majchrzak A; Jeske A; Darzynkiewicz Z; Ardelt W; Ardelt B; Robak T
    Int J Oncol; 2014 Jul; 45(1):419-25. PubMed ID: 24789756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.